Norma Bloy

Cornell University — United States

Medicine · Health Sciences

25h-index4.0kcitations71works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(21), Immunotherapy and Immune Responses(21), Advanced Breast Cancer Therapies(17), Immune Cell Function and Interaction(11), Cancer-related Molecular Pathways(10)

Publications71 total

Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages
Nature Cancer·2025· 2 citedOpen Access
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages
Nature Cancer·2025· 10 cited
Abstract B075: Antitumor immune responses to different Radiation Therapy doses and fractionation schedules in a preclinical model of hormone receptor positive breast cancer
Cancer Immunology Research·2025
Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis
JNCI Journal of the National Cancer Institute·2024· 9 citedOpen Access
Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
Journal of Visualized Experiments·2024· 1 cited
Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line
Methods in cell biology·2024· 1 citedOpen Access
1440 Shaping the immunometabolism of HR+ breast cancer with kynurenamines
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
858 Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors
Methods in cell biology·2023
Data from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figure 1 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figure 2 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Data from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figure 1 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Data from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figure 2 from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Data from Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER<sup>+</sup> Breast Cancer
2023Open Access
Abstract P6-11-07: Role of insulin resistance in HR+ mammary carcinogenesis
Cancer Research·2023
Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
Journal of Translational Medicine·2023· 18 citedOpen Access
Quantification of beta-galactosidase activity as a marker of radiation-driven cellular senescence
Methods in cell biology·2022· 3 cited
page 1 of 4Next →

Frequent Co-authors

Aitziber Buqué(36), Lorenzo Galluzzi(36), Guido Kroemer(32), Laurence Zitvogel(21), Giulia Petroni(16), Jitka Fučíková(15), Jérôme Galon(15), Takahiro Yamazaki(15), Fernando Aranda(14), Isabelle Cremer(14), Alexander Eggermont(14), Ai Sato(14), Laura Senovilla(12), Jonathan Pol(12), Radek Špíšek(12), Silvia C. Formenti(10), Éric Tartour(10), Erika Vacchelli(9), Wolf H. Fridman(9), Juliette Humeau(7)